

REMARKS

Applicants' claims are directed to methods and compositions for the treatment of diabetes. These claims are based on applicants' discovery that insulin-producing cells transduced with an inhibitor of apoptosis polypeptide (IAP) are more likely to survive transplantation into a diabetic subject than control cells.

Support for the Amendments

The specification has been amended to specify the priority information. Support for this amendment is found in Form PTO-1382, at section II.

Support for the amendment of the claims is found throughout the specification as originally filed. For example, support for the amendment of claims 1 and 63, which now recite "cells express a transgene," is found at page 13, lines 6-17, and at page 14, lines 30-31; support for the amendment of claims 1 and 63, and for new claims 63, 64, and 69, which now recite "a fragment" of an IAP polypeptide is found, for example, at page 9, lines 1-4; support for the amendment of claims 1, 7 and 63, and for new claim 69, which recite "a constitutive promoter" or "an inducible or cell-specific promoter" is found, for example, at page 3, lines 8-13; support for the amendment of claim 15, which now recites "capable of producing progeny cells that are insulin-producing cells" is found at original claim 1; support for the amendment of claims 1, 20, 23, 63, and 69, which now recite that control cells are "not expressing said IAP," is found at page 26, lines 20-27; support for the amendment of claim 20, which now recites "control" is found, for example, at original

claim 23; support for the amendment of claim 23 and for new claim 69, which recite “expression of said IAP polypeptide increases survival of said cells” is found, for example, at original claim 1; support for the amendment of claim 54, which now recites “subject” is found at original claim 1; support for the amendment of claim 56, which now recites “sufficient to inhibit apoptosis” is found at original claim 57; support for new claim 64, which is directed to a XIAP fragment comprising at least one BIR domain, is found at original claim 12; support for new claim 65, which recites “BIR3” is found at page 24, lines 29-31; support for claim 66, which recites a “beta-islet cell” is found, for example, at page 3, lines 28-30; support for claim 67, which recites “*in situ*” is found, for example, at page 5, line 4; support for claim 68, is found at original claim 1; support for new claim 69 is found at original claim 63.

No new matter has been added.

SUMMARY


If there are any charges or any credits, please apply them to Deposit Account

No. 03-2095.

Date:

July 22, 2004

Respectfully submitted,



Kristina Bieker-Brady, Ph.D., P.C.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045